A clinical trial is a carefully supervised research study conducted in human volunteers to evaluate an experimental drug that has not yet been made available to the general public. Clinical trials play an important role in the approval of a new medicine by demonstrating that it can effectively treat patients at a safe dose. Anyone interested in participating in a clinical study should be well informed about the study and discuss any questions or concerns with their physician and healthcare providers prior to enrolling in the study.
A Phase 2a Study of LAM-001 for the Treatment of PH
To learn more, click here to visit ClinicalTrials.gov. (ClinicalTrials.gov Identifier: NCT05798923)
A Phase 2 Study of LAM-001 in Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome
To learn more, click here to visit ClinicalTrials.gov. (ClinicalTrials.gov Identifier: NCT06018766)
OrphAI Therapeutics is committed to developing promising new therapies to address the unmet medical needs of patients suffering from rare orphan conditions. Our goal is to provide access to our medicines at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe focusing on enrollment in our ongoing clinical trials is the safest and most effective way of achieving this goal.
We do recognize that some patients will not be eligible for our clinical trials and may wish to access our investigational products through expanded access. At present, OrphAI Therapeutics is evaluating the benefit/risk profile of our investigational therapies and is dedicating all resources available toward developing these therapies to support regulatory approvals and its current patient commitments. As such, OrphAI Therapeutics is currently unable to offer Right to Try or new expanded access use of our investigational medicines.
We encourage all patients and physicians who are interested in accessing our investigational medicines to review the information on this page about enrolling in our clinical trials.
AI Therapeutics may revise this expanded access policy at any time.
